Literature DB >> 1414416

The effect of long-term lithium treatment on the mortality of patients with manic-depressive and schizoaffective illness.

B Müller-Oerlinghausen1, B Ahrens, E Grof, P Grof, G Lenz, M Schou, C Simhandl, K Thau, J Volk, R Wolf.   

Abstract

Clinical research centers in Aarhus, Berlin, Hamilton and Vienna collected mortality data for 827 manic-depressive and schizoaffective patients given lithium treatment for more than 6 months. The average duration of the treatment was 81 months and the total time on lithium 5600 patient-years. For each patient, the mortality risk was calculated by entering the appropriate national life tables for the general population. The number of observed deaths was 44; the number of expected deaths was 49.7. The standardized mortality ratio, 0.89, did not differ significantly from 1.0. The mortality of manic-depressive patients is 2-3 times that of the general population. Our data show that the mortality of manic-depressive and schizoaffective patients given long-term lithium treatment does not differ significantly from that of the general population.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1414416     DOI: 10.1111/j.1600-0447.1992.tb03255.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  16 in total

Review 1.  [Anti-suicidal effect of lithium: current state of research and its clinical implications for the long-term treatment of affective disorders].

Authors:  U Lewitzka; M Bauer; W Felber; B Müller-Oerlinghausen
Journal:  Nervenarzt       Date:  2013-03       Impact factor: 1.214

Review 2.  A speculative model of affective illness cyclicity based on patterns of drug tolerance observed in amygdala-kindled seizures.

Authors:  R M Post; S R Weiss
Journal:  Mol Neurobiol       Date:  1996-08       Impact factor: 5.590

Review 3.  Prevention of suicide: aspirations and evidence.

Authors:  D Gunnell; S Frankel
Journal:  BMJ       Date:  1994-05-07

Review 4.  Management options for bipolar disorder in children and adolescents.

Authors:  Arman Danielyan; Robert A Kowatch
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

Review 5.  [Psychopharmaceuticals for treatment of suicidal patients and for suicide prevention].

Authors:  R Haußmann; M Bauer; U Lewitzka; B Müller-Oerlinghausen
Journal:  Nervenarzt       Date:  2016-05       Impact factor: 1.214

6.  Lithium treatment and thyroid abnormalities.

Authors:  Alberto Bocchetta; Andrea Loviselli
Journal:  Clin Pract Epidemiol Ment Health       Date:  2006-09-12

7.  Renal function during long-term lithium treatment: a cross-sectional and longitudinal study.

Authors:  Alberto Bocchetta; Raffaella Ardau; Tiziana Fanni; Claudia Sardu; Doloretta Piras; Antonello Pani; Maria Del Zompo
Journal:  BMC Med       Date:  2015-01-21       Impact factor: 8.775

8.  The suicide prevention effect of lithium: more than 20 years of evidence-a narrative review.

Authors:  U Lewitzka; E Severus; R Bauer; P Ritter; B Müller-Oerlinghausen; M Bauer
Journal:  Int J Bipolar Disord       Date:  2015-07-18

9.  Duration of lithium treatment is a risk factor for reduced glomerular function: a cross-sectional study.

Authors:  Alberto Bocchetta; Raffaella Ardau; Paolo Carta; Franca Ligas; Claudia Sardu; Antonello Pani; Maria Del Zompo
Journal:  BMC Med       Date:  2013-02-11       Impact factor: 8.775

10.  Assessment of Response to Lithium Maintenance Treatment in Bipolar Disorder: A Consortium on Lithium Genetics (ConLiGen) Report.

Authors:  Mirko Manchia; Mazda Adli; Nirmala Akula; Raffaella Ardau; Jean-Michel Aubry; Lena Backlund; Claudio Em Banzato; Bernhard T Baune; Frank Bellivier; Susanne Bengesser; Joanna M Biernacka; Clara Brichant-Petitjean; Elise Bui; Cynthia V Calkin; Andrew Tai Ann Cheng; Caterina Chillotti; Sven Cichon; Scott Clark; Piotr M Czerski; Clarissa Dantas; Maria Del Zompo; J Raymond Depaulo; Sevilla D Detera-Wadleigh; Bruno Etain; Peter Falkai; Louise Frisén; Mark A Frye; Jan Fullerton; Sébastien Gard; Julie Garnham; Fernando S Goes; Paul Grof; Oliver Gruber; Ryota Hashimoto; Joanna Hauser; Urs Heilbronner; Rebecca Hoban; Liping Hou; Stéphane Jamain; Jean-Pierre Kahn; Layla Kassem; Tadafumi Kato; John R Kelsoe; Sarah Kittel-Schneider; Sebastian Kliwicki; Po-Hsiu Kuo; Ichiro Kusumi; Gonzalo Laje; Catharina Lavebratt; Marion Leboyer; Susan G Leckband; Carlos A López Jaramillo; Mario Maj; Alain Malafosse; Lina Martinsson; Takuya Masui; Philip B Mitchell; Frank Mondimore; Palmiero Monteleone; Audrey Nallet; Maria Neuner; Tomás Novák; Claire O'Donovan; Urban Osby; Norio Ozaki; Roy H Perlis; Andrea Pfennig; James B Potash; Daniela Reich-Erkelenz; Andreas Reif; Eva Reininghaus; Sara Richardson; Guy A Rouleau; Janusz K Rybakowski; Martin Schalling; Peter R Schofield; Oliver K Schubert; Barbara Schweizer; Florian Seemüller; Maria Grigoroiu-Serbanescu; Giovanni Severino; Lisa R Seymour; Claire Slaney; Jordan W Smoller; Alessio Squassina; Thomas Stamm; Jo Steele; Pavla Stopkova; Sarah K Tighe; Alfonso Tortorella; Gustavo Turecki; Naomi R Wray; Adam Wright; Peter P Zandi; David Zilles; Michael Bauer; Marcella Rietschel; Francis J McMahon; Thomas G Schulze; Martin Alda
Journal:  PLoS One       Date:  2013-06-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.